???global.info.a_carregar???
Miren Ettcheto is Assistant Professor at the Department of Pharmacology, Toxicology and Therapeutic Chemistry of the Faculty of Pharmacy at the University of Barcelona (UB). She graduated in 2012 in Biology specialized in health in the Faculty of Biology (UB). She hold a Master in Biomedicine from the same university and she carried out her Master thesis in the research group lead by Prof. Antoni Camins. After that, she started her PhD in the same research group and she focused her studies in the search of new therapeutic strategies for Alzheimer's disease. In 2018, she did her PhD dissertation and she continued in the field of Neuropharmacology and neurodegenerative diseases. During this time, she has given lessons in different Universities, she has been supervisor of many students and she has carried out internships in different reference centers including Hannover Medical School (Germany) and National Institute for Public Health and the Environment in Utrecht (Netherlands) which has allow her to enrich her scientific background. During this time, she has been part of Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED) and she has published around 80 works mainly in the field of Neuroscience and Pharmacology which have allow her to obtain more than 2800 cites and a H-index of 28.
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Miren Ettcheto Arriola

Nomes de citação

  • Ettcheto, Miren

Identificadores de autor

Ciência ID
7817-9C44-7D48
ORCID iD
0000-0002-4301-7297
Formação
Grau Classificação
2018/03/16
Concluído
 Recerca, desenvolupament i control de medicaments (Doctor)
Universitat de Barcelona Departament de Farmacologia Toxicologia i Química Terapèutica, Espanha
"Efecto del síndrome metabólico provocado por una dieta rica en grasa en ratones appswe/ps1de9, modelo experimental de la enfermedad de alzheimer, y posibles terapias farmacológicas" (TESE/DISSERTAÇÃO)
2013/09
Concluído
 Biomedicina (Master)
Universitat de Barcelona, Espanha
2012/07/30
Concluído
 Biologia (Graduado)
Universitat de Barcelona, Espanha
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento 		Empregador
2021 - Atual Investigador (Investigação) Universitat de Barcelona, Espanha
2014/06/01 - Atual Investigador Contratado (Investigação) Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Espanha
Universitat de Barcelona, Espanha
Projetos

Outro

Designação Financiadores
2022/01/01 - Atual Papel de los micro-RNAs circulantes como potenciales biomarcadores y dianas terapeuticas de la resistencia a la insulina y la enfermedad de Alzheimer
PI2021/03
Investigador
Em curso
2018/07/01 - Atual Mención de Excelencia Maria de Maetzu al Institut de Neurociències de la Universitat de Barcelona (UBNEURO)
MDM-2017-0729
Investigador
Em curso
2006/11/17 - Atual Enfermedades neurodegenerativas
CB06/05/0024
Investigador
Em curso
2022/09/01 - 2026/08/31 Biomarcadores en exosomas plasmáticos para el diagnóstico temprano de la enfermedad de Alzheimer prodrómica. (BIOPEXAL)
PID2021-122473OA-I00
Co-Investigador Responsável (Co-IR)
Em curso
2016/01/01 - 2025/05/15 ORFILA
GINDOC-UB/105
Investigador
Em curso
2023 - 2025 Grup de Recerca en Envelliment i Neurodegeneració
SGR2021 00288
Em curso
2023/01/02 - 2024/07/02 Epigenetic modulation of blood-brain barrier integrity for the prevention of epileptogenesis
2022.03133.PTDC
Investigador
2019/03/21 - 2023/01/31 Noves polimixines per al tractament d'infeccions causades per bacteris multiresistents (MARATO TV3 201829-10)
201829-10
Investigador
Concluído
2020/09/14 - 2022/03/31 Desenvolupament i avaluació d’un cas pràctic integrador i transversal al Màster Universitari de Recerca, Desenvolupament i Control de Medicaments
2020PID-UB/016
Investigador
Concluído
2018/01/01 - 2021/12/31 Modulación de la vía del receptor de la insulina hipocampal como estrategia terapéutica para el tratamiento de la pérdida cognitiva
SAF-2017-84283-R
Investigador
Concluído
2017/01/01 - 2021/09/30 Grup de Recerca en Envelliment i Neurodegeneració
2017SGR625
Investigador
Concluído
2016/12/01 - 2018/12/31 Alteraciones del metabolismo gluco-lipidico y desarrollo de la demencia de Alzheimer
PI2016/01-3
Investigador
Concluído
2014/01/01 - 2017/04/30 Grup de Recerca en envelliment i neurodegeneració (GREN)
2014SGR525
Outra
Concluído
Produções

Publicações

Artigo em revista
  1. Santos, A.B.; Carona, Andreia; Ettcheto, Miren; Camins, Antoni; Falcão Amílcar; Fortuna, Ana; Bicker, Joana. "Krüppel-like factors: potential roles in blood-brain barrier dysfunction and epileptogenesis". Acta Pharmacologica Sinica (2024):
    Aceite para publicação • 10.1038/s41401-024-01285-w
  2. Fonseca, Carla; Cunha, Susana; Lapo Pais, Mariana; Gonçalves, Joana; Ferreira, Nuno Ricardo Esteves; Camins, Antoni; Ettcheto, Miren; Barbosa, Rui; Fortuna, Ana. "Cannabinoid Modulation of Monoamine Levels in Mouse Brain: Unveiling Neurochemical Dynamics through an Innovative High-performance Liquid Chromatography-Fluorescence Detection Bioanalysis". Journal of Analysis and Testing (2024):
    Aceite para publicação • 10.1007/s41664-024-00307-0
  3. Melina Rojas-Criollo; Nil Novau-Ferré; Laia Gutierrez-Tordera; Miren Ettcheto; Jaume Folch; Christopher Papandreou; Laura Panisello; et al. "Effects of a High-Fat Diet on Insulin-Related miRNAs in Plasma and Brain Tissue in APPSwe/PS1dE9 and Wild-Type C57BL/6J Mice". Nutrients (2024): https://doi.org/10.3390/nu16070955.
    10.3390/nu16070955
  4. Gouveia F; Fonseca C; Silva A; Camins A; Teresa Cruz M; Ettcheto M; Fortuna A. "Intranasal irbesartan reverts cognitive decline and activates the PI3K/AKT pathway in an LPS-induced neuroinflammation mice model.". International immunopharmacology (2024): http://europepmc.org/abstract/med/38199198.
    10.1016/j.intimp.2023.111471
  5. Gutierrez-Tordera L; Papandreou C; Novau-Ferré N; García-González P; Rojas M; Marquié M; Chapado LA; et al. "Exploring small non-coding RNAs as blood-based biomarkers to predict Alzheimer's disease.". Cell & bioscience (2024): http://europepmc.org/abstract/med/38229129.
    10.1186/s13578-023-01190-5
  6. Jordi Olloquequi; Miren Ettcheto; Amanda Cano; Ana Fortuna; Joana Bicker; Elena Sánchez-Lopez; Cristian Paz; et al. "Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment". International Journal of Molecular Sciences (2023): https://doi.org/10.3390/ijms241814177.
    10.3390/ijms241814177
  7. Gerard Esteruelas; Alba Ortiz; Josefina Prat; Estefania Vega; Montserrat Muñoz-Juncosa; Maria Luisa Garcia López; Miren Ettcheto; et al. "Novel customized age-dependent corneal membranes and interactions with biodegradable nanoparticles loaded with dexibuprofen". Colloids and Surfaces B: Biointerfaces (2023): https://doi.org/10.1016/j.colsurfb.2023.113394.
    10.1016/j.colsurfb.2023.113394
  8. Saghar Rabieipoor; Meysam Zare; Miren Ettcheto; Antoni Camins; Mohammad Javan. "Metformin restores cognitive dysfunction and histopathological deficits in an animal model of sporadic Alzheimer's disease". Heliyon (2023): https://doi.org/10.1016/j.heliyon.2023.e17873.
    10.1016/j.heliyon.2023.e17873
  9. Fonseca C; Ettcheto M; Bicker J; Fernandes MJ; Falcão A; Camins A; Fortuna A. "Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy?". Ageing research reviews (2023): http://europepmc.org/abstract/med/37414155.
    10.1016/j.arr.2023.101998
  10. Espinosa-Jiménez T; Cano A; Sánchez-López E; Olloquequi J; Folch J; Bulló M; Verdaguer E; et al. "A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer's disease exacerbated with high fat diet.". Cell & bioscience (2023): http://europepmc.org/abstract/med/36895036.
    10.1186/s13578-023-01000-y
  11. Amanda Cano; Álvaro Muñoz-Morales; Elena Sánchez-López; Miren Ettcheto; Eliana B. Souto; Antonio Camins; Mercè Boada; Agustín Ruíz. "Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges". Pharmaceutics (2023): https://doi.org/10.3390/pharmaceutics15010298.
    10.3390/pharmaceutics15010298
  12. Cano A; Ettcheto M; Bernuz M; Puerta R; Esteban de Antonio E; Sánchez-López E; Souto EB; et al. "Extracellular vesicles, the emerging mirrors of brain physiopathology.". International journal of biological sciences (2023): http://europepmc.org/abstract/med/36778117.
    10.7150/ijbs.79063
  13. Kühne BA; Teixidó E; Ettcheto M; Puig T; Planas M; Feliu L; Pla L; et al. "Application of the adverse outcome pathway to identify molecular changes in prenatal brain programming induced by IUGR: Discoveries after EGCG exposure.". Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2022): http://europepmc.org/abstract/med/36370916.
    10.1016/j.fct.2022.113506
  14. Olloquequi J; Cano A; Sanchez-López E; Carrasco M; Verdaguer E; Fortuna A; Folch J; et al. "Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders.". Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2022): http://europepmc.org/abstract/med/36126456.
    10.1016/j.biopha.2022.113709
  15. Espinosa-Jiménez T; Busquets O; Cano A; Sánchez-López E; Verdaguer E; Parcerisas A; Olloquequi J; et al. "Peroxisomal Proliferator-Activated Receptor ß/d Deficiency Induces Cognitive Alterations.". Frontiers in pharmacology (2022): http://europepmc.org/abstract/med/35899125.
    10.3389/fphar.2022.902047
  16. Busquets O; Espinosa-Jiménez T; Ettcheto M; Olloquequi J; Bulló M; Carro E; Cantero JL; et al. "JNK1 and JNK3: divergent functions in hippocampal metabolic-cognitive function.". Molecular medicine (Cambridge, Mass.) (2022): http://europepmc.org/abstract/med/35508978.
    10.1186/s10020-022-00471-y
  17. Olloquequi J; Ettcheto M; Cano A; Sanchez-López E; Carrasco M; Espinosa T; Beas-Zarate C; et al. "Impact of New Drugs for Therapeutic Intervention in Alzheimer's Disease.". Frontiers in bioscience (Landmark edition) (2022): http://europepmc.org/abstract/med/35638413.
    10.31083/j.fbl2705146
  18. Gouveia F; Camins A; Ettcheto M; Bicker J; Falcão A; Cruz MT; Fortuna A. "Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future.". Ageing research reviews (2022): http://europepmc.org/abstract/med/35346852.
    10.1016/j.arr.2022.101612
  19. Ruth Galindo; Elena Sánchez López; María José Gómara; Marta Espina; Miren Ettcheto; Amanda Cano; Isabel Haro; Antoni Camins; María Luisa García. "Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation". Pharmaceutics (2022): https://www.mdpi.com/1999-4923/14/2/285.
    10.3390/pharmaceutics14020285
  20. Camins A; Ettcheto M. "Therapeutic Strategies for Neurological Disorders: From Natural Compounds to Innovative Molecular Designs.". Current pharmaceutical design (2022): http://europepmc.org/abstract/med/35856262.
    10.2174/138161282814220713113802
  21. Busquets, O.; Ettcheto, M.; Pallàs, M.; Beas-Zarate, C.; Verdaguer, E.; Auladell, C.; Folch, J.; Camins, A.. "Corrigendum to “Long-term exposition to a high fat diet favors the appearance of ß-amyloid depositions in the brain of C57BL/6 J mice. A potential model of sporadic Alzheimer's disease” [J. Mech. Ageing Dev. 162 (March) (2017) 38-45](S0047637416300859)(10.1016/j.mad.2016.11.002)". Mechanisms of Ageing and Development 201 (2022): http://www.scopus.com/inward/record.url?eid=2-s2.0-85123651669&partnerID=MN8TOARS.
    10.1016/j.mad.2021.111615
  22. Esteruelas, G.; Halbaut, L.; García-Torra, V.; Espina, M.; Cano, A.; Ettcheto, M.; Camins, A.; et al. "Development and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment". International Journal of Pharmaceutics 612 (2022): http://www.scopus.com/inward/record.url?eid=2-s2.0-85121212234&partnerID=MN8TOARS.
    10.1016/j.ijpharm.2021.121379
  23. Lorena Bonilla Vidal; Marta Espina; Patrícia Severino; Amanda Cano; Miren Ettcheto; Antoni Camins; Maria Luisa García; Souto, E.B.; Elena Sánchez López. "Lipid Nanoparticles for the Posterior Eye Segment". Pharmaceutics (2021): https://www.mdpi.com/1999-4923/14/1/90.
    10.3390/pharmaceutics14010090
  24. Amanda Cano; Elena Fonseca; Miren Ettcheto; Elena Sánchez López; Itziar de Rojas; Silvia Alonso-Lana; Xavier Morató; et al. "Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways". Pharmaceuticals (2021): https://www.mdpi.com/1424-8247/14/10/1057.
    10.3390/ph14101057
  25. Saghar Rabiei Poor; Miren Ettcheto; Amanda Cano; Elena Sánchez López; Patricia Manzine; Jordi Olloquequi; Antoni Camins; Mohammad Javan. "Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer’s Disease Treatment". Pharmaceuticals (2021): https://www.mdpi.com/1424-8247/14/9/890.
    10.3390/ph14090890
  26. Rubén D. Castro-Torres; Jordi Olloquequi; Miren Ettcheto; Pablo Caruana; Luke Steele; Kyra-Mae Leighton; Jesús Ureña; et al. "Dual Mkk4 and Mkk7 Gene Deletion in Adult Mouse Causes an Impairment of Hippocampal Immature Granule Cells". International Journal of Molecular Sciences (2021): https://www.mdpi.com/1422-0067/22/17/9545.
    10.3390/ijms22179545
  27. VICTOR GARCIA TORRA; Amanda Cano; Marta Espina; Miren Ettcheto; Antoni Camins; Emma Barroso; Manuel Vazquez-Carrera; et al. "State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks". Toxics (2021): https://www.mdpi.com/2305-6304/9/8/195.
    10.3390/toxics9080195
  28. Laura Del Amo; Amanda Cano; Miren Ettcheto; Eliana B. Souto; Marta Espina; Antoni Camins; Maria Luísa García; Elena Sánchez López. "Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer’s Disease". Applied Sciences (2021): https://www.mdpi.com/2076-3417/11/9/4305.
    10.3390/app11094305
  29. Claudia Taborda Gómez; Fabiana Lairion; Marisa Repetto; Miren Ettcheto; Amalia Merelli; Alberto Lazarowski; Jerónimo Auzmendi. "Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment". Pharmaceuticals (2021): https://www.mdpi.com/1424-8247/14/3/220.
    10.3390/ph14030220
  30. Busquets, O.; Carrasco, M.; Espinosa-Jiménez, T.; Ettcheto, M.; Verdaguer, E.; Auladell, C.; Bullò, M.; et al. "GSPE pre-treatment protects against long-term cafeteria diet-induced mitochondrial and inflammatory affectations in the hippocampus of rats". Nutritional Neuroscience (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85119452054&partnerID=MN8TOARS.
    10.1080/1028415X.2021.1995118
  31. Ettcheto, M.; Busquets, O.; Cano, A.; Sánchez-Lopez, E.; Manzine, P.R.; Espinosa-Jimenez, T.; Verdaguer, E.; et al. "Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease". Journal of Alzheimer's Disease 82 s1 (2021): S91-S107. http://www.scopus.com/inward/record.url?eid=2-s2.0-85108784130&partnerID=MN8TOARS.
    10.3233/JAD-201106
  32. Ettcheto, M.; Cano, A.; Sanchez-López, E.; Verdaguer, E.; Folch, J.; Auladell, C.; Camins, A.. "Masitinib for the treatment of alzheimer's disease". Neurodegenerative Disease Management 11 4 (2021): 263-276. http://www.scopus.com/inward/record.url?eid=2-s2.0-85115049268&partnerID=MN8TOARS.
    10.2217/nmt-2021-0019
  33. Busquets, O.; Parcerisas, A.; Verdaguer, E.; Ettcheto, M.; Camins, A.; Beas-Zarate, C.; Castro-Torres, R.D.; Auladell, C.. "C-Jun N-Terminal Kinases in Alzheimer's Disease: A Possible Target for the Modulation of the Earliest Alterations". Journal of Alzheimer's Disease 82 s1 (2021): S127-S139. http://www.scopus.com/inward/record.url?eid=2-s2.0-85100100261&partnerID=MN8TOARS.
    10.3233/JAD-201053
  34. Cano, A.; Turowski, P.; Ettcheto, M.; Duskey, J.T.; Tosi, G.; Sánchez-López, E.; García, M.L.; et al. "Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges". Journal of Nanobiotechnology 19 1 (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85104932868&partnerID=MN8TOARS.
    10.1186/s12951-021-00864-x
  35. Cano, A.; Ettcheto, M.; Espina, M.; Auladell, C.; Folch, J.; Kühne, B.A.; Barenys, M.; et al. "Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice". Nanomedicine 16 1 (2021): 19-35. http://www.scopus.com/inward/record.url?eid=2-s2.0-85099584876&partnerID=MN8TOARS.
    10.2217/nnm-2020-0239
  36. Viayna, E.; Coquelle, N.; Cieslikiewicz-Bouet, M.; Cisternas, P.; Oliva, C.A.; Sánchez-López, E.; Ettcheto, M.; et al. "Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice". Journal of Medicinal Chemistry 64 1 (2021): 812-839. http://www.scopus.com/inward/record.url?eid=2-s2.0-85100069324&partnerID=MN8TOARS.
    10.1021/acs.jmedchem.0c01775
  37. Bonilla, L.; Esteruelas, G.; Ettcheto, M.; Espina, M.; García, M.L.; Camins, A.; Souto, E.B.; Cano, A.; Sánchez-López, E.. "Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges". Epilepsia Open (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85120967364&partnerID=MN8TOARS.
    10.1002/epi4.12567
  38. Ettcheto, M.; Sánchez-Lopez, E.; Cano, A.; Carrasco, M.; Herrera, K.; Manzine, P.R.; Espinosa-Jimenez, T.; et al. "Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice". Cell and Bioscience 11 1 (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85111296685&partnerID=MN8TOARS.
    10.1186/s13578-021-00646-w
  39. Rubén D. Castro-Torres; Busquets O; Antoni Parcerisas; Ester Verdaguer; Jordi Olloquequi; Miren Ettcheto; Carlos Beas-Zarate; et al. "Involvement of JNK1 in Neuronal Polarization During Brain Development". Cells (2020): https://www.mdpi.com/2073-4409/9/8/1897.
    10.3390/cells9081897
  40. Carme Auladell; Rubén D. Castro-Torres; Oriol Busquets; Miren Ettcheto; Antoni Camins; Ester Verdaguer. "JNK isoforms control mammal adult hippocampal neurogenesis". Mexican Journal of Medical Research ICSA 8 16 (2020): 5-12. https://doi.org/10.29057/mjmr.v8i16.5548.
    10.29057/mjmr.v8i16.5548
  41. "Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice". Molecular Neurobiology (2020): http://dx.doi.org/10.1007/s12035-019-01849-6.
    10.1007/s12035-019-01849-6
  42. Elena Sánchez López; Gerard Esteruelas; Alba Ortiz; Marta Espina; Josefina Prat; Montserrat Muñoz; Amanda Cano; et al. "Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study". Nanomaterials (2020): https://www.mdpi.com/2079-4991/10/4/720.
    10.3390/nano10040720
  43. "Chronological review of potential disease modifying therapeutic strategies for Alzheimer's disease.". Current Pharmaceutical Design (2020): http://dx.doi.org/10.2174/1381612826666200211121416.
    10.2174/1381612826666200211121416
  44. "Metal-Based Nanoparticles as Antimicrobial Agents: An Overview". Nanomaterials (2020): http://dx.doi.org/10.3390/nano10020292.
    10.3390/nano10020292
  45. "Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia". Frontiers in Aging Neuroscience (2020): http://dx.doi.org/10.3389/fnagi.2019.00344.
    10.3389/fnagi.2019.00344
  46. Ettcheto, M.; Busquets, O.; Sánchez-Lopez, E.; Cano, A.; Manzine, P.R.; Verdaguer, E.; Olloquequi, J.; et al. "The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease". Expert Opinion on Drug Discovery 15 9 (2020): 993-1004. http://www.scopus.com/inward/record.url?eid=2-s2.0-85086026359&partnerID=MN8TOARS.
    10.1080/17460441.2020.1767580
  47. Ettcheto, M.; Sánchez-López, E.; Gómez-Mínguez, Y.; Cabrera, H.; Busquets, O.; Beas-Zarate, C.; García, M.L.; et al. "Correction to: Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer’s Disease (Molecular Neurobiology, (2018), 55, 9, (7327-7339), 10.1007/s12035-018-0868-4)". Molecular Neurobiology 57 6 (2020): 2887-2888. http://www.scopus.com/inward/record.url?eid=2-s2.0-85085096971&partnerID=MN8TOARS.
    10.1007/s12035-020-01918-1
  48. Cano, A.; Ettcheto, M.; Espina, M.; López-Machado, A.; Cajal, Y.; Rabanal, F.; Sánchez-López, E.; et al. "State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections". Journal of Nanobiotechnology 18 1 (2020): http://www.scopus.com/inward/record.url?eid=2-s2.0-85094847482&partnerID=MN8TOARS.
    10.1186/s12951-020-00714-2
  49. Cano, A.; Sánchez-López, E.; Ettcheto, M.; López-Machado, A.; Espina, M.; Souto, E.B.; Galindo, R.; et al. "Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases". Nanomedicine 15 12 (2020): 1239-1261. http://www.scopus.com/inward/record.url?eid=2-s2.0-85085904151&partnerID=MN8TOARS.
    10.2217/nnm-2019-0443
  50. "Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment". International Journal of Molecular Sciences (2019): http://dx.doi.org/10.3390/ijms21010255.
    10.3390/ijms21010255
  51. "c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments". Journal of Molecular Medicine (2019): http://dx.doi.org/10.1007/s00109-019-01856-z.
    10.1007/s00109-019-01856-z
  52. "The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer’s Dementia". Frontiers in Aging Neuroscience (2019): http://dx.doi.org/10.3389/fnagi.2019.00236.
    10.3389/fnagi.2019.00236
  53. "Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents". Pharmaceutics (2019): http://dx.doi.org/10.3390/pharmaceutics11090460.
    10.3390/pharmaceutics11090460
  54. "Isoform-selective as opposed to complete depletion of fibroblast growth factor 2 (FGF-2) has no major impact on survival and gene expression in SOD1 G93A amyotrophic lateral sclerosis mice". European Journal of Neuroscience (2019): http://dx.doi.org/10.1111/ejn.14405.
    10.1111/ejn.14405
  55. "JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy". Molecular Neurobiology (2019): http://dx.doi.org/10.1007/s12035-019-1476-7.
    10.1007/s12035-019-1476-7
  56. "A metabolic perspective of late onset Alzheimer’s disease". Pharmacological Research (2019): http://dx.doi.org/10.1016/j.phrs.2019.104255.
    10.1016/j.phrs.2019.104255
  57. "Current Applications of Nanoemulsions in Cancer Therapeutics". Nanomaterials (2019): http://dx.doi.org/10.3390/nano9060821.
    10.3390/nano9060821
  58. "ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker". Biomedicine & Pharmacotherapy (2019): http://dx.doi.org/10.1016/j.biopha.2019.108661.
    10.1016/j.biopha.2019.108661
  59. "Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model". Journal of Controlled Release (2019): http://dx.doi.org/10.1016/j.jconrel.2019.03.010.
    10.1016/j.jconrel.2019.03.010
  60. "Characterizing the multiple roles of FGF-2 in SOD1G93A ALS mice in vivo and in vitro". Journal of Cellular Physiology (2019): http://dx.doi.org/10.1002/jcp.27498.
    10.1002/jcp.27498
  61. "Role of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model". Journal of Neurochemistry (2019): http://dx.doi.org/10.1111/jnc.14682.
    10.1111/jnc.14682
  62. "Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer’s disease". Expert Opinion on Investigational Drugs (2019): http://dx.doi.org/10.1080/13543784.2019.1552677.
    10.1080/13543784.2019.1552677
  63. "Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease". Neural Regeneration Research (2019): http://dx.doi.org/10.4103/1673-5374.257513.
    10.4103/1673-5374.257513
  64. Cano, A.; Ettcheto, M.; Espina, M.; Sánchez-López, E.; López, A.L.; Camins, A.; García, M.L.. "Nanopartícules polimèriques d'epigalocatequina-3-galat, un enfocament nanotecnològic per tractar la malaltia d'Alzheimer". Circular Farmaceutica 77 1 (2019): 5-8. http://www.scopus.com/inward/record.url?eid=2-s2.0-85072685966&partnerID=MN8TOARS.
  65. "Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization". Journal of Nanobiotechnology (2018): http://dx.doi.org/10.1186/s12951-018-0356-z.
    10.1186/s12951-018-0356-z
  66. "The Ethyl Acetate Extract of Leaves of Ugni molinae Turcz. Improves Neuropathological Hallmarks of Alzheimer’s Disease in Female APPswe/PS1dE9 Mice Fed with a High Fat Diet". Journal of Alzheimer's Disease (2018): http://doi.org/10.3233/JAD-180174.
    10.3233/JAD-180174
  67. "Experimental Models for Aging and their Potential for Novel Drug Discovery". Current Neuropharmacology (2018): http://dx.doi.org/10.2174/1570159x15666170707155345.
    10.2174/1570159x15666170707155345
  68. "Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer’s Disease". Molecular Neurobiology (2018): http://dx.doi.org/10.1007/s12035-018-0868-4.
    10.1007/s12035-018-0868-4
  69. "Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy". Nanomedicine: Nanotechnology, Biology and Medicine (2018): http://dx.doi.org/10.1016/j.nano.2018.01.019.
    10.1016/j.nano.2018.01.019
  70. "Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimer’s Disease". Molecular Neurobiology (2018): http://dx.doi.org/10.1007/s12035-017-0690-4.
    10.1007/s12035-017-0690-4
  71. "Memantine for the Treatment of Dementia: A Review on its Current and Future Applications". Journal of Alzheimer's Disease (2018): http://doi.org/10.3233/JAD-170672.
    10.3233/JAD-170672
  72. "JNK1 inhibition by Licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid". Neuropharmacology (2018): http://dx.doi.org/10.1016/j.neuropharm.2017.10.030.
    10.1016/j.neuropharm.2017.10.030
  73. "The Implication of the Brain Insulin Receptor in Late Onset Alzheimer’s Disease Dementia". Pharmaceuticals (2018): http://dx.doi.org/10.3390/ph11010011.
    10.3390/ph11010011
  74. "Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína ß-amiloide". Neurología (2018): http://dx.doi.org/10.1016/j.nrl.2015.03.012.
    10.1016/j.nrl.2015.03.012
  75. "Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma". Small (2018): http://dx.doi.org/10.1002/smll.201701808.
    10.1002/smll.201701808
  76. "Review of the advances in treatment for Alzheimer disease: strategies for combating ß-amyloid protein". Neurología (English Edition) (2018): http://dx.doi.org/10.1016/j.nrleng.2015.03.019.
    10.1016/j.nrleng.2015.03.019
  77. "Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe / PS1dE9 through multiple signaling pathways". Redox Biology (2017): http://dx.doi.org/10.1016/j.redox.2017.06.003.
    10.1016/j.redox.2017.06.003
  78. "Anti-inflammatory role of Leptin in glial cells through p38 MAPK pathway inhibition". Pharmacological Reports (2017): http://dx.doi.org/10.1016/j.pharep.2016.12.005.
    10.1016/j.pharep.2016.12.005
  79. "New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9". Nanomedicine: Nanotechnology, Biology and Medicine (2017): http://dx.doi.org/10.1016/j.nano.2016.12.003.
    10.1016/j.nano.2016.12.003
  80. "Long-term exposition to a high fat diet favors the appearance of ß-amyloid depositions in the brain of C57BL/6J mice. A potential model of sporadic Alzheimer’s disease". Mechanisms of Ageing and Development (2017): http://dx.doi.org/10.1016/j.mad.2016.11.002.
    10.1016/j.mad.2016.11.002
  81. "Role of JNK isoforms in the kainic acid experimental model of epilepsy and neurodegeneration". Frontiers in Bioscience (2017): http://dx.doi.org/10.2741/4517.
    10.2741/4517
  82. "Evaluation of the Role of JNK1 in the Hippocampus in an Experimental Model of Familial Alzheimer’s Disease". Molecular Neurobiology (2016): http://dx.doi.org/10.1007/s12035-015-9522-6.
    10.1007/s12035-015-9522-6
  83. "PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen—in vitro, ex vivo and in vivo characterization". Colloids and Surfaces B: Biointerfaces (2016): http://dx.doi.org/10.1016/j.colsurfb.2016.04.054.
    10.1016/j.colsurfb.2016.04.054
  84. "Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alzheimer’s Disease Stage in APP/PS1 Mice". Journal of Alzheimer's Disease (2016): http://doi.org/10.3233/JAD-160150.
    10.3233/JAD-160150
  85. "Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment". Neural Plasticity (2016): http://dx.doi.org/10.1155/2016/8501693.
    10.1155/2016/8501693
  86. "The role of leptin in the sporadic form of Alzheimer's disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin". Life Sciences (2015): http://dx.doi.org/10.1016/j.lfs.2015.05.002.
    10.1016/j.lfs.2015.05.002
  87. "Mice Lacking Functional Fas Death Receptors Are Protected from Kainic Acid-Induced Apoptosis in the Hippocampus". Molecular Neurobiology (2015): http://dx.doi.org/10.1007/s12035-014-8836-0.
    10.1007/s12035-014-8836-0
  88. "Masitinib for the treatment of mild to moderate Alzheimer’s disease". Expert Review of Neurotherapeutics (2015): http://dx.doi.org/10.1586/14737175.2015.1045419.
    10.1586/14737175.2015.1045419
  89. "Hypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APPswe/PS1dE9 mice". Experimental Gerontology (2015): http://dx.doi.org/10.1016/j.exger.2015.03.010.
    10.1016/j.exger.2015.03.010
Livro
  1. Sánchez-López, E.; Souto, E.B.; Espina, M.; Cano, A.; Ettcheto, M.; Camins, A.; García, M.L.. Nanoparticle Products for the Eye: Preformulation, Formulation, and Manufacturing Considerations. 2021.
    10.1007/978-3-030-76367-1_15
Poster em conferência
  1. Gouveia, Filipa; Fonseca, Carla; Bicker, Joana; Camins, Antoni; Cruz, Maria Teresa; Ettcheto, Miren; Fortuna Ana. "Intranasal Administration of Irbesartan as a New Strategy for Addressing Neurodegeneration in a Neuroinflammation Mice Model: Pharmacokinetic and Efficacy Evaluation". Trabalho apresentado em Congresso do Núcleo de Estudantes de Farmácia da Associação Académica de Coimbra, 2024.
  2. Fonseca, Carla; Lapo Pais, Mariana; Bicker, Joana; Carona, Andreia; Ferreira, Ricardo; Barbosa, Rui M.; Camins, Antoni; Ettcheto, Miren; Fortuna, Ana. "A new bioanalytical tool for neurotransmitter monitoring in central nervous system diseases". Trabalho apresentado em 2nd Annual Meeting of CIBIT, 2023.
  3. Gouveia, Filipa; Bicker, Joana; Carona, Andreia; Ettcheto, Miren; Cruz, Maria Teresa; Fortuna, Ana. "Ultra High Performance Liquid Chromatography Technique to support Pharmacokinetic Monitoring of Losartan, Irbesartan and Valsartan". Trabalho apresentado em X Congresso Iberoamericano de Ciências Farmacêuticas, 2023.
  4. Gouveia, Filipa; Fonseca, Carla; Ana Silva; Antoni Camins; Maria Tereza Cruz; Ettcheto, Miren; Fortuna, Ana. "Angiotensin Receptor Blockers as an Alternative Strategy for Addressing Neurodegeneration in a LPS Mice Model". Trabalho apresentado em Alzheimer’s Association International Congress, 2023.
  5. Gouveia, Filipa; Camins, Antoni; Ettcheto, Miren; Maria Teresa Rosete; Fortuna, Ana. "Renin-angiotensin system acting drugs: a possible role in Alzheimer’s disease". Trabalho apresentado em International Multi-Brain Barcelona Congress - Healthy, Pathological and Artificial Brain, 2022.
  6. Fonseca, Carla; Ettcheto, Miren; Camins, Antoni; Ferreira Nuno; Bicker, Joana; Barbosa, Rui; Fortuna, Ana. "New HPLC technology for monitoring neurotransmitters in the brain: a pre-clinical approach for neurological disorders". Trabalho apresentado em ternational Multi-Brain Barcelona Congress - Healthy, Pathological and Artificial Brain, 2022.
Pré-impressão
  1. Miren Ettcheto; Elena Sánchez-Lopez; Amanda Cano; Marina Carrasco; Katherine Herrera; Patricia R. Manzine; Triana Espinosa-Jimenez; et al. "Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice". 2021. https://doi.org/10.21203/rs.3.rs-415246/v1.
    10.21203/rs.3.rs-415246/v1
Atividades

Orientação

Título / Tema
Papel desempenhado 		Curso (Tipo)
Instituição / Organização
2023/10/01 - Atual Biomarcadores en exosomas plasmáticos para el diagnóstico temprano de la enfermedad de Alzheimer prodrómica. (BIOPEXAL) / BIOmarkers of Plasma EXosomes for the early diagnosis of prodromal ALzheimer’s disease.
Coorientador
2023/10 - Atual Novel psychedelics as promising disease-modifying treatment in neurodegenerative and neuropsychiatric disorders.
Coorientador
2023 - Atual Claramina: inhibidor de PTTP1B como estrategia terapeutica para potenciar la resistencia cognitiva en la enfermedad de Alzheimer y otras enfermedades neurodegenerativas
Orientador
2022 - Atual Estratègies terapèutiques per a incrementar la resiliencia cognitiva
Orientador
2021/10 - Atual Strive Against Alzheimer's Disease Through the modulation of depressive state and the use of cannabinoids?
Coorientador
2020/10 - Atual ----
Coorientador
Universitat de Barcelona, Espanha
2020/09 - Atual Targeting the brain renin-angiotensin system by nose-to-brain delivery for prevention and treatment of Alzheimer's disease
Coorientador
2020 - Atual Avaluació de noves polimixines i teràpies nefro- i neuro- protectores com a estratégias per al tractament d'infeccions causadles per bacteria multiresistents
Orientador
2023 - 2023 Neuroprotective effect of Licochalcone A in APPswe/PS1dE9 exacerbated with high-fat diet as a preclinical model of Alzheimer's Disease.
Orientador
Universitat Autònoma de Barcelona, Espanha
2023 - 2023 Estudio del papel de la tirosina fosfatasa-1B (PTP1B) sobre la cognición en un modelo animal de inflamación sistémica
Orientador
2023 - 2023 DETERMINACIÓN DEL EFECTO NEUROPROTECTOR DEL DEXIBUPROFENO-HUPRINA EN UN MODELO MURINO DE NEUROINFLAMACIÓN
Orientador
Universitat de Barcelona, Espanha
2023 - 2023 Dietary intervention, a promising approach to diminish the adverse effects of exposure to air pollution
Coorientador de Blanca León
2023 - 2023 Estudio del efecto neuroprotector de licochalcona-A en ratones APPswe/PS1dE9 como modelo de la enfermedad de alzheimer
Orientador
2023 - 2023 Peptide functionalized biodegradable Riluzole-loaded nanoparticles for the treatment of Alzheimer's disease
Coorientador
2023 - 2023 Nanopartículas funcionalizadas de PLGA para el tratamiento del Alzheimer: una aproximación in vivo
Coorientador
2019 - 2023 “El déficit cognitivo y la enfermedad de Alzheimer en presencia de alteraciones metabólicas: Estudio in vivo de una nueva diana terapéutica y de la estrategia multi-diana para el tratamiento de estas condiciones”
Coorientador
Universitat de Barcelona, Espanha
2022 - 2022 Efecte neuroprotector de l'EGCG contra la malaltia de Huntington induïda per 3-NP
Orientador
Universitat Autònoma de Barcelona, Espanha
2021 - 2021/07 Study of the protective effect of epigallocatechin gallate on epilepsy related neurodegeneration
Orientador
2021 - 2021/06/30 Evaluation of the protective effects of Licochalcone a in a murine neuroinflammation model
Orientador
Universitat Autònoma de Barcelona, Espanha
2020/01 - 2020/07 Efecto protector del pistacho en el desarrollo de enfermedades
Orientador
2020/01 - 2020/07 Dexibuprofen improves cognitive decline in APP/PS1 mice fed with an obesogenic diet through regulating peripheral metabolic alterations
Orientador
2020 - 2020/07 Dieta rica en grasa: factor de riesgo en la enfermedad de Alzheimer
Orientador
2020 - 2020/07 Epigalocatequina-3-galato, nueva estrategia terapéutica para revertir el déficit cognitivo inducido por la inyección de Ácido 3-nitropropiónico, modelo de la Enfermedad de Huntington en ratones
Orientador
Universitat de Barcelona, Espanha
2019 - 2019/07 Protección de la epigalocatequina-3-galato (EGCG) frente a la neurodegeneración producida en el modelo animal de epilepsia del lóbulo temporal inducido por ácido kaínico
Orientador
Universitat Autònoma de Barcelona, Espanha
2019 - 2019 Papel de la dieta rica en grasa en la enfermedad de Alzheimer
Orientador
2019 - 2019 EGCG protects against cognitive deficit in the murine kainic acid model, experimental model of temporal lobe epilepsy
Orientador
Universitat de Barcelona, Espanha
2018 - 2019 Papel de la vía de la JNK1 en el proceso cognitivo “
Coorientador
2018 - 2018 Nanopartículas biodegradables de Dexibuprofeno-Huprina para el tratamiento de enfermedades neurodegenerativas
Coorientador
2016 - 2017 Efecto del dexiibuprofeno (DXI) en ratones APPswe/PS1dE9, modelo experimental de la enfermedad de Alzheimer familiar, alimentados con dieta rica en grasa”
Coorientador
Distinções

Prémio

2020 Jorge Heller Award
Controlled Release Society (CRS) , Estados Unidos